NCT06994676View on ClinicalTrials.gov

A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

June 30, 2027

Conditions
High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)AML - Acute Myeloid Leukemia
Interventions
DRUG

CBX-250

subcutaneous CBX-250

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

33612

RECRUITING

Moffitt Cancer Center, Tampa

37203

RECRUITING

Sarah Cannon Cancer Institute, Nashville

37232

RECRUITING

Vanderbilt University Medical Center, Nashville

63110

RECRUITING

Washington University in St. Louis, St Louis

77030

RECRUITING

MD Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope, Duarte

Sponsors
All Listed Sponsors
lead

Crossbow Therapeutics, Inc.

INDUSTRY

NCT06994676 - A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Biotech Hunter | Biotech Hunter